Portfolio
Phibro Animal Health Corporation
| Investment type | Growth capital |
|---|---|
| Status | Current investment |
Nature of Business
Phibro Animal Health Corporation (Phibro) is a global leader in animal health & nutrition and related performance products, with thousands of customers worldwide and a global workforce of around 1,000 employees.
Phibro serves customers globally through manufacturing and distributing more than 550 speciality products. Its combined annual sales are more than $600 million. Phibro is headquartered in Ridgefield Park, New Jersey and has offices across the US and around the world.
Investment Overview
3i QPE originally invested in March 2008, listing the business on AIM and engaging with Phibro management to support an international expansion strategy and to allow for a more diversified product portfolio. Following the acquisition of 3i QPE by 3i Group, Phibro became part of 3i’s core Growth Capital portfolio and in June 2010 was de-listed from AIM.
Since our investment, we have been actively involved in delivering growth in emerging markets, particularly Brazil, Russia, India and China and 3i Partner, Sundip Murthy has joined the Board. In 2009 we advised on the acquisition of vaccines specialist, ABIC, and nutritionals business, Baltzell.
In the last year, we have assisted the Company to refinance its existing debt, supported the de-listing from AIM, reviewed a number of international growth opportunities, and recruited an additional Board member, Carol Wrenn, the former CEO of Alpharma.